See more : YGSOFT Inc. (002063.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of OraSure Technologies, Inc. (OSUR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of OraSure Technologies, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Shanghai Lonyer Fuels Co., Ltd. (603003.SS) Income Statement Analysis – Financial Results
- Krsnaa Diagnostics Limited (KRSNAA.BO) Income Statement Analysis – Financial Results
- Recrusul S/A (RCSL4.SA) Income Statement Analysis – Financial Results
- Kingdee International Software Group Company Limited (0268.HK) Income Statement Analysis – Financial Results
- Newcore Gold Ltd. (NCAUF) Income Statement Analysis – Financial Results
OraSure Technologies, Inc. (OSUR)
About OraSure Technologies, Inc.
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 405.47M | 387.48M | 233.67M | 171.72M | 154.61M | 181.74M | 167.06M | 128.20M | 119.72M | 106.46M | 98.94M | 87.82M | 81.88M | 75.02M | 77.03M | 71.10M | 82.69M | 68.15M | 69.37M | 54.01M | 40.45M | 32.01M | 32.57M | 30.10M | 10.10M | 9.80M | 9.40M | 68.70M | 5.00M | 4.80M | 3.30M | 3.00M | 3.80M | 3.60M | 3.20M |
| Cost of Revenue | 226.05M | 239.84M | 116.07M | 69.85M | 60.02M | 68.13M | 68.11M | 40.17M | 39.43M | 39.84M | 40.35M | 32.25M | 30.16M | 27.66M | 29.90M | 29.98M | 32.40M | 24.76M | 27.97M | 22.14M | 16.06M | 12.89M | 12.33M | 9.00M | 3.10M | 3.00M | 2.80M | 58.60M | 4.90M | 5.60M | 1.70M | 1.20M | 1.90M | 2.00M | 4.20M |
| Gross Profit | 179.42M | 147.64M | 117.60M | 101.87M | 94.58M | 113.61M | 98.96M | 88.03M | 80.29M | 66.62M | 58.59M | 55.57M | 51.72M | 47.36M | 47.13M | 41.13M | 50.28M | 43.40M | 41.39M | 31.87M | 24.39M | 19.12M | 20.24M | 21.10M | 7.00M | 6.80M | 6.60M | 10.10M | 100.00K | -800.00K | 1.60M | 1.80M | 1.90M | 1.60M | -1.00M |
| Gross Profit Ratio | 44.25% | 38.10% | 50.33% | 59.32% | 61.18% | 62.51% | 59.23% | 68.66% | 67.07% | 62.58% | 59.22% | 63.28% | 63.16% | 63.13% | 61.19% | 57.84% | 60.81% | 63.68% | 59.67% | 59.00% | 60.29% | 59.74% | 62.14% | 70.10% | 69.31% | 69.39% | 70.21% | 14.70% | 2.00% | -16.67% | 48.48% | 60.00% | 50.00% | 44.44% | -31.25% |
| Research & Development | 33.73M | 36.24M | 34.17M | 31.03M | 19.63M | 16.25M | 13.37M | 9.75M | 11.65M | 12.06M | 10.93M | 12.45M | 18.41M | 13.19M | 13.37M | 20.26M | 14.14M | 8.65M | 5.27M | 6.06M | 8.00M | 8.27M | 9.39M | 10.40M | 4.00M | 2.90M | 4.20M | 4.50M | 6.80M | 6.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 58.19M | 68.21M | 50.33M | 42.65M | 35.29M | 38.33M | 29.32M | 28.36M | 25.49M | 23.75M | 21.65M | 22.31M | 20.33M | 16.79M | 18.30M | 37.20M | 37.37M | 29.29M | 28.55M | 27.16M | 17.68M | 14.39M | 14.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 36.32M | 49.24M | 44.75M | 34.46M | 31.87M | 30.61M | 28.53M | 29.65M | 35.09M | 41.12M | 46.47M | 37.09M | 22.38M | 20.73M | 21.22M | 20.92B | 20.06B | 15.92B | 16.06B | 15.15B | 10.76B | 8.07B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 92.18M | 117.44M | 95.08M | 77.11M | 67.16M | 68.93M | 57.85M | 58.01M | 60.58M | 64.87M | 68.12M | 59.40M | 42.71M | 37.52M | 39.52M | 37.20M | 37.37M | 29.29M | 28.55M | 27.16M | 17.68M | 14.39M | 14.73M | 13.81M | 5.70M | 5.40M | 6.70M | 9.80M | 11.20M | 7.80M | 13.90M | 8.20M | 6.10M | 4.40M | 1.40M |
| Other Expenses | 0.00 | 6.48M | 872.00K | 1.65M | 2.72M | 3.29M | 794.00K | 58.00K | 774.00K | 531.00K | 200.00K | -242.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.10M | 700.00K | 700.00K | 700.00K | 1.30M | 1.50M | 1.20M | 1.10M | 1.20M | 900.00K | 500.00K | 300.00K |
| Operating Expenses | 146.74M | 153.68M | 129.25M | 108.14M | 86.79M | 85.18M | 71.22M | 67.76M | 72.24M | 76.93M | 79.05M | 71.84M | 61.12M | 50.71M | 52.89M | 57.46M | 51.50M | 37.94M | 33.82M | 33.22M | 25.68M | 22.66M | 24.12M | 26.31M | 10.40M | 9.00M | 11.60M | 15.60M | 19.50M | 15.10M | 15.00M | 9.40M | 7.00M | 4.90M | 1.70M |
| Cost & Expenses | 372.79M | 393.52M | 245.32M | 178.00M | 146.81M | 153.31M | 139.33M | 107.93M | 111.66M | 116.77M | 119.40M | 104.09M | 91.28M | 78.37M | 82.79M | 87.44M | 83.91M | 62.69M | 61.79M | 55.36M | 41.74M | 35.55M | 36.46M | 35.31M | 13.50M | 12.00M | 14.40M | 74.20M | 24.40M | 20.70M | 16.70M | 10.60M | 8.90M | 6.90M | 5.90M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 63.99K | 151.76K | 737.89K | 3.08B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 10.43M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 172.00K | 316.31K | 316.19K | 361.19K | 345.77K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.52M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 20.94M | 14.00M | 11.66M | 9.39M | 7.34M | 6.45M | 6.40M | 5.69M | 5.70M | 6.31M | 6.49M | 7.25M | 4.89M | 3.01M | 3.05M | 3.39M | 2.74M | 1.92M | 2.35M | 2.49M | 2.58M | 2.18M | 2.00M | 2.10M | 700.00K | 700.00K | 700.00K | 1.30M | 1.50M | 1.20M | 1.10M | 1.20M | 900.00K | 500.00K | 300.00K |
| EBITDA | 64.35M | 10.29M | 9.00K | 3.44M | 15.53M | 34.88M | 34.14M | 26.01M | 8.06M | -4.00M | -13.91M | -9.09M | -4.50M | -168.49K | -5.02M | -5.02M | 1.52M | 7.39M | 9.92M | 1.13M | 1.29M | -1.36M | -1.89M | -4.42M | -2.70M | -1.50M | -4.30M | -4.20M | -10.10M | -14.70M | -12.30M | -6.40M | -4.20M | -2.80M | -2.40M |
| EBITDA Ratio | 15.87% | 2.81% | -5.62% | -4.29% | 3.05% | 19.62% | 12.95% | 15.81% | 11.49% | -8.92% | -22.51% | -10.27% | -11.10% | -4.28% | -2.57% | -25.02% | 0.23% | 10.98% | 14.22% | 2.19% | 3.34% | -4.25% | -4.73% | 13.02% | -26.73% | -19.39% | -54.26% | -13.97% | -376.00% | -308.33% | -333.33% | -223.33% | -115.79% | -88.89% | -81.25% |
| Operating Income | 54.08M | -4.67M | -11.65M | -6.28M | -3.02M | 28.43M | 40.24M | 20.27M | 8.06M | -4.80M | -12.16M | -16.27M | -9.40M | -3.35M | -8.79M | -16.33M | -1.22M | 5.46M | 7.57M | -1.36M | -1.29M | -3.54M | -4.33M | -12.81M | -3.40M | -2.20M | -5.00M | -5.50M | -19.40M | -15.90M | -13.40M | -7.60M | -5.10M | -3.30M | -2.70M |
| Operating Income Ratio | 13.34% | -1.20% | -4.99% | -3.65% | -1.95% | 15.64% | 24.09% | 15.81% | 6.73% | -4.51% | -12.29% | -18.53% | -11.48% | -4.47% | -11.42% | -22.97% | -1.47% | 8.02% | 10.92% | -2.51% | -3.18% | -11.06% | -13.30% | -42.56% | -33.66% | -22.45% | -53.19% | -8.01% | -388.00% | -331.25% | -406.06% | -253.33% | -134.21% | -91.67% | -84.38% |
| Total Other Income/Expenses | 2.18M | -9.63M | 872.00K | 1.65M | 2.72M | 3.29M | 794.00K | 58.00K | 774.00K | 531.00K | 200.00K | -242.00K | -312.57K | -142.84K | 357.15K | 7.58M | 5.51M | 3.60M | 2.15M | 797.04K | 176.80K | 198.06K | 633.49K | 90.89K | 200.00K | 400.00K | 800.00K | 5.00M | 11.60M | 100.00K | -1.30M | 300.00K | 200.00K | 400.00K | 200.00K |
| Income Before Tax | 56.26M | -16.48M | -9.29M | -3.52M | 21.33M | 31.72M | 41.03M | 20.32M | 8.83M | -4.27M | -11.96M | -16.51M | -9.71M | -3.50M | -8.44M | -8.75M | 4.29M | 9.06M | 9.72M | -559.64K | -1.11M | -3.34M | -3.70M | -12.72M | -3.20M | -1.90M | -22.50M | -300.00K | -18.50M | -15.60M | -14.70M | -7.20M | -4.90M | -2.90M | -2.60M |
| Income Before Tax Ratio | 13.87% | -4.25% | -3.98% | -2.05% | 13.80% | 17.45% | 24.56% | 15.85% | 7.38% | -4.01% | -12.09% | -18.80% | -11.86% | -4.66% | -10.95% | -12.30% | 5.19% | 13.30% | 14.01% | -1.04% | -2.74% | -10.44% | -11.36% | -42.26% | -31.68% | -19.39% | -239.36% | -0.44% | -370.00% | -325.00% | -445.45% | -240.00% | -128.95% | -80.56% | -81.25% |
| Income Tax Expense | 2.60M | 1.46M | 13.71M | 11.40M | 4.68M | 11.32M | 10.08M | 603.00K | 665.00K | 343.00K | -772.00K | -1.40M | -869.00K | 142.84K | -622.28K | 22.53M | 1.82M | 3.79M | -17.73M | -797.04K | 26.59K | -198.06K | 28.79K | 24.36K | 3.20M | 1.90M | 22.50M | 300.00K | 18.50M | 15.60M | 14.70M | 7.20M | 4.90M | 2.90M | 2.60M |
| Net Income | 53.66M | -17.94M | -23.00M | -14.92M | 16.66M | 20.40M | 30.95M | 19.72M | 8.17M | -4.61M | -11.19M | -15.12M | -8.84M | -3.50M | -7.81M | -31.28M | 2.47M | 5.27M | 27.45M | -559.64K | -1.14M | -3.34M | -3.73M | -12.75M | -3.20M | -1.90M | -22.50M | -300.00K | -18.50M | -15.60M | -14.70M | -7.20M | -4.90M | -2.90M | -2.60M |
| Net Income Ratio | 13.23% | -4.63% | -9.84% | -8.69% | 10.77% | 11.22% | 18.52% | 15.38% | 6.82% | -4.33% | -11.31% | -17.21% | -10.80% | -4.66% | -10.14% | -43.99% | 2.99% | 7.73% | 39.57% | -1.04% | -2.81% | -10.44% | -11.44% | -42.34% | -31.68% | -19.39% | -239.36% | -0.44% | -370.00% | -325.00% | -445.45% | -240.00% | -128.95% | -80.56% | -81.25% |
| EPS | 0.73 | -0.25 | -0.32 | -0.22 | 0.27 | 0.33 | 0.52 | 0.35 | 0.14 | -0.08 | -0.20 | -0.29 | -0.19 | -0.08 | -0.17 | -0.67 | 0.05 | 0.11 | 0.61 | -0.01 | -0.03 | -0.09 | -0.10 | -0.36 | -0.23 | -0.14 | -1.12 | -0.02 | -1.04 | -1.07 | -1.11 | -0.55 | -0.43 | -0.29 | -0.31 |
| EPS Diluted | 0.72 | -0.25 | -0.32 | -0.22 | 0.27 | 0.33 | 0.51 | 0.35 | 0.14 | -0.08 | -0.20 | -0.29 | -0.19 | -0.08 | -0.17 | -0.67 | 0.05 | 0.11 | 0.59 | -0.01 | -0.03 | -0.09 | -0.10 | -0.36 | -0.23 | -0.14 | -1.12 | -0.02 | -1.04 | -1.07 | -1.11 | -0.55 | -0.43 | -0.29 | -0.31 |
| Weighted Avg Shares Out | 73.35M | 72.51M | 71.98M | 67.51M | 61.68M | 61.11M | 59.05M | 55.62M | 56.40M | 55.95M | 55.56M | 51.46M | 46.91M | 46.19M | 45.88M | 46.55M | 46.33M | 45.91M | 45.11M | 44.46M | 39.79M | 37.58M | 36.87M | 35.00M | 13.91M | 13.57M | 20.10M | 18.90M | 17.79M | 14.61M | 13.24M | 13.09M | 11.40M | 10.00M | 8.39M |
| Weighted Avg Shares Out (Dil) | 74.39M | 72.51M | 71.98M | 67.51M | 62.17M | 62.53M | 61.02M | 56.51M | 56.85M | 55.95M | 55.56M | 51.46M | 46.91M | 46.19M | 45.88M | 46.55M | 46.88M | 46.58M | 46.15M | 44.46M | 39.79M | 37.58M | 36.87M | 35.00M | 13.91M | 13.57M | 20.10M | 18.90M | 17.79M | 14.61M | 13.24M | 13.09M | 11.40M | 10.00M | 8.39M |
OraSure Technologies to Present at Stephens Annual Investment Conference
BETHLEHEM, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analytical services, today announced that Ken McGrath, Chief Financial Officer, will participate in a...
OraSure Technologies, Inc. (OSUR) Q3 2022 Earnings Call Transcript
OraSure Technologies, Inc. (NASDAQ:OSUR ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Scott Gleason - Senior Vice President of Communications and Investor Relations Carrie Manner - President and Chief Executive Officer Kenneth McGrath -...
OraSure Technologies (OSUR) Q3 Earnings and Revenues Top Estimates
OraSure (OSUR) delivered earnings and revenue surprises of 216.67% and 26.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
2022 Third Quarter Earnings Conference Call Tuesday, November 8, 2022, 5:00 p.m. ET
BETHLEHEM, Pa., Nov. 01, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 third quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Tuesday, November...
3 Penny Stocks That Are Too Cheap to Ignore
The traditional definition of penny stocks is those companies whose shares trade for $5 or less. It's never easy finding cheap penny stocks to buy amongst this oppressed group because they are often selling at a low share price for...
OraSure Technologies, Inc. (OSUR) CEO Carrie Manner on Q2 2022 Results - Earnings Call Transcript
OraSure Technologies, Inc. (NASDAQ:OSUR ) Q2 2022 Earnings Conference Call August 9, 2022 5:00 PM ET Company Participants Scott Gleason - Senior Vice President of Investor Relations & Corporate Communications Carrie Manner - President & Chief Executive Officer Kathleen Weber...
OraSure Technologies (OSUR) Reports Break-Even Earnings for Q2
OraSure (OSUR) delivered earnings and revenue surprises of 100% and 13.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies to Hold 2022 Second Quarter Earnings Conference Call Tuesday, August 9, 2022, 5:00 p.m. ET
BETHLEHEM, Pa., Aug. 02, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 second quarter financial results and certain business developments for 5:00 p.m. ET (2:00 p.m. PT) on Tuesday, August...
OraSure Technologies, Inc. (OSUR) CEO Nancy Gagliano on Q1 2022 Results - Earnings Call Transcript
OraSure Technologies, Inc. (NASDAQ:OSUR ) Q1 2022 Earnings Conference Call May 10, 2022 5:00 PM ET Company Participants Kathleen Weber - President of Molecular Solutions Lisa Nibauer - President of Diagnostics Nancy Gagliano - Interim Chief Executive Officer & Director...
OraSure Technologies (OSUR) Reports Q1 Loss, Tops Revenue Estimates
OraSure (OSUR) delivered earnings and revenue surprises of -100% and 4.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Source: https://incomestatements.info
Category: Stock Reports